N4 Pharma's Nuvec granted patent in India

N4 PharmaSharecast graphic / Josh White

N4 Pharma

0.65p

16:55 19/11/24

0.00%

0.00p

N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

FTSE AIM All-Share

724.23

16:59 19/11/24

n/a

Pharmaceuticals & Biotechnology

19,328.21

16:34 19/11/24

0.64%

123.81

The AIM-traded firm said the newly-granted patent in India encompassed both the composition of matter patent for the Nuvec particle itself, and the associated manufacturing process.

It said the achievement aligned with previously-granted patents in various regions, including the US, Canada, Europe, Japan, Australia and China.

“The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec,” said chief executive officer Nigel Theobald.

At 1111 GMT, shares in N4 Pharma were up 3.09% at 1p.

Reporting by Josh White for Sharecast.com.

{{ storiesRelated.title }}